Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome [8]

Leukemia

Volumn 17, Issue 6, 2003, Pages 1200-1202

  Strupp, C ^a   Hildebrandt, B ^a   Germing, U ^a   Haas, R ^a   Gattermann, N ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; METHOTREXATE; PHENPROCOUMON; THALIDOMIDE; TIOGUANINE; TREOSULFAN;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CYTOGENETICS; DOSE RESPONSE; DRUG MECHANISM; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; KARYOTYPING; LABORATORY TEST; LETTER; MALE; MYELODYSPLASTIC SYNDROME; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; WHOLE BODY RADIATION;

EID: 0038040494     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402894     Document Type: Letter

References (8)

1. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002; 16: 1-6.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
4. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
5. Canepa L, Ballerini F, Varaldo R, Quintino S, Reni L, Clavio M et al. Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 2001; 115: 313-315.
6. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958-965.
7. Zorat F, Shetty V, Dutt D, Lisak L, Nascimben F, Allampallam K et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 2001; 115: 881-894.
8. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clin Exp Immunol 2002; 130: 75-84.